NCT02073487 - Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2019

Conditions

Breast Cancer

Interventions

DRUG

T-DM1

antibody-drug conjugate of trastuzumab and emtansine

DRUG

Trastuzumab

anti-Her2 monoclonal antibody

DRUG

Lapatinib

Dual tyrosine kinase inhibitor (HER2 and EGFR)

DRUG

Abraxane

albumin-bound paclitaxel. chemotherapy - microtubule inhibitor.

DRUG

Paclitaxel

chemotherapy - microtubule inhibitor

DRUG

Pertuzumab

anti-HER2 monoclonal antibody

Trial Locations (3)

Houston Methodist Hospital, Houston

Houston Methodist Hospital Willowbrook, Houston

Houston Methodist Hospital Sugar Land, Sugar Land